Positive results show that the average weight loss was 12.5 kg (11.8% body weight reduction) with cagrilintide compared to 2.5 kg (2.3%) with placebo, after 68 weeks *1,2 Cagrilintide was ...
The Andhra Pradesh State Council of Higher Education (APSCHE) has released the AP EAMCET 2025 phase 3 and final seat allotment results at eapcet-sche.aptonline.in. Candidates must download their ...
The self joining and reporting at allotted colleges will be carried out on or before September 23, 2025, and classwork will commence from September 20, 2025. AP EAMCET 2025: How to check seat ...
AI-generated edits have become a huge craze online, with each new prompt sparking its own viral moment. Before the much-loved saree trend filled feeds with vintage Bollywood-style portraits, another ...
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...
TPAO has awarded additional contracts for additional development of Sakarya gas field in the Black Sea. Phase 3 involves a new floating production unit, 27 wells, and a 183-km export pipeline ...
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...
Investing.com -- aTyr Pharma (NASDAQ:ATYR) stock fell 80% after the company announced that its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint. The ...
Sept 11 (Reuters) - Microsoft (MSFT.O), opens new tab and OpenAI said on Thursday they have signed a non-binding deal for new relationship terms that would allow OpenAI to proceed to restructure ...
First patient dosed in study of novel EP4 antagonist for advanced solid tumours Nxera Pharma and Cancer Research UK have announced the first patient has been dosed in a phase 2a trial of HTL0039732, ...
Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking an Ionis-partnered candidate that could offer dosing just once a year into pivotal trials on the strength of ...
Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with short ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback